From the Guidelines
Anoro Ellipta contains two active ingredients: umeclidinium and vilanterol, which work together to improve breathing in patients with chronic obstructive pulmonary disease (COPD). The medication umeclidinium is a long-acting muscarinic antagonist (LAMA) that relaxes the muscles around the airways, while vilanterol is a long-acting beta2-adrenergic agonist (LABA) that helps open the airways 1. Some of the key points about these ingredients include:
- Umeclidinium and vilanterol are both once-daily long-acting agents that offer the potential adherence and therapeutic advantage of once-daily therapy.
- The combination of vilanterol and umeclidinium was recently approved by the Food and Drug Administration for COPD as once-daily combination bronchodilator therapy, as mentioned in the study published in Chest 1.
- This dual mechanism of action provides better bronchodilation than either medication alone, making it effective for maintenance treatment of airflow obstruction in COPD patients.
- It's essential to use this medication regularly as prescribed, even when feeling well, and to avoid using it for acute breathing problems or asthma attacks as it's not intended for rescue therapy.
From the FDA Drug Label
Active ingredients: umeclidinium, vilanterol The active ingredients of Anoro Ellipta are umeclidinium and vilanterol 2.
From the Research
Active Ingredients of Anoro
- The active ingredients of Anoro are umeclidinium and vilanterol, which are a long-acting muscarinic receptor antagonist and a long-acting β2-adrenoceptor agonist, respectively 3, 4, 5, 6, 7.
Mechanism of Action
- Umeclidinium works by blocking the action of acetylcholine, a neurotransmitter that causes airway smooth muscle contraction, while vilanterol works by stimulating the β2-adrenergic receptors, leading to bronchodilation 3, 4, 5, 6, 7.
Dosage and Administration
- Anoro is administered once daily using the Ellipta multi-dose dry powder inhaler, with a delivered dose of 55/22 μg once daily 3.